<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00379431</url>
  </required_header>
  <id_info>
    <org_study_id>2006/257</org_study_id>
    <nct_id>NCT00379431</nct_id>
  </id_info>
  <brief_title>A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), Rituximab</brief_title>
  <official_title>A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), Rituximab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rituximab 1000 mg i.v. will be given on day 1 and 15, week 26 - 28, together with a
      corticosteroid regimen consisting of methylprednisolone 100 mg i.v. 30 minutes prior to both
      infusions.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2006</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>28 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart failure defined as a LVEF&lt; 30%</measure>
    <time_frame>28 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lung failure defined as a resting PaO2&lt; 60mmHg</measure>
    <time_frame>28 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evolution of antibody titers.</measure>
    <time_frame>28 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Deterioration, improvement or stabilisation of, disease activity score, 6-m walking distance, SHAQ, LVEF and creatinine clearance</measure>
    <time_frame>28 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Early and Severe Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>Administration of rituximab and methylprednisolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration of rituximab and methylprednisolone</intervention_name>
    <description>Rituximab:
Pharmaceutical form: Concentrate for solution for infusion. Maximum duration of treatment: 28 weeks Maximum dose allowed: 2000 mg (use of total dose) Route of administration: intravenous use.</description>
    <arm_group_label>Administration of rituximab and methylprednisolone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female &gt;= 18 years

          -  SSc according to the ARA criteria for systemic sclerosis

          -  Disease duration less than 4 years (from the appearance of skin changes (oedema,
             fibrosis)

          -  Inadequate response to methotrexate (at least 12 weeks 10 mg/w, except if not
             tolerated

          -  Antibodies specific for systemic sclerosis: anti-topoisomerase; anti-centromere
             antibodies

          -  Severe disease defined by either one of the following: a modified Rodnan skin score
             (TSS° &gt;= 14 ), disease activity score &gt;= 3

          -  Contraception for women with childbearing potential. Sexual abstinence is an
             alternative to contraception.

          -  Patient has signed informed consent.

        Exclusion Criteria:

          -  disease duration more than 4 years

          -  FVC &lt;= 50%

          -  LVEF &lt;= 40% of predicted value

          -  DLCO &lt;= 40% of predicted value

          -  Lack of peripheral venous access

          -  Pregnancy or breast feeding

          -  Significant cardiac or pulmonary disease (including obstructive pulmonary disease),
             evidence of significant uncontrolled concomitant disease such as, but not limited to,
             nervous system, renal, hepatic, endocrine or gastrointestinal disorders which, in the
             investigator's opinion, would preclude patient participation

          -  Primary or secondary immunodeficiency (history of, or currently active), including
             known history of HIV infection.

          -  Known active infection of any kind (excluding fungal infections of mail beds), or any
             major episode of infection requiring hospitalization or treatment with i.v.
             anti-infectives within 4 weeks of baseline or completion of oral anti-infectives
             within 2 weeks prior to baseline.

          -  History of deep space/tissue infection (e.g. fasciitis, abscess, osteomyelitis) within
             52 weeks prior to baseline.

          -  History of serious recurrent or chronic infection (for screening for a chest infection
             a chest radiograph will be performed at screening if not performed within 12 weeks
             prior to screening).

          -  History of cancer, including solid tumors, hematologic malignancies and carcinoma in
             situ (except basal cell and squamous cell carcinoma of the skin that have been excised
             and cured).

          -  History of a severe allergic or anaphylactic reaction to a biologic agent or known
             hypersensitivity to any component of rituximab or to murine proteins.

          -  Concurrent treatment with any biologic agent or DMARD other than MTX. Treatment must
             be discontinued 14 days prior to baseline , except for the following: azathioprine for
             ≥ 28 days; leflunomide for ≥ 8 weeks (or ≥ 14 days after 11 days of standard
             cholestyramine or activated charcoal washout); infliximab ≥ 8 weeks; adalimumab ≥
             weeks.

          -  Previous treatment with &gt; 1 biological agent.

          -  Previous treatment with any cell depleting therapies, including investigational
             agents.

          -  Treatment with any investigational agent within 28 days of baseline or 5 half-lives of
             the investigational drug (xhich ever is the longer).

          -  Receipt of any vaccine within 28 days prior to baseline

          -  Intolerance or contraindications to i.v. glucocorticoids.

          -  Positive serum human chorionic gonadotropin (hCG) measured at screening or a positive
             pregnancy test prior to the first rituximab infusion.

          -  Positive tests for hepatitis B surface antigen (HBsAg), hepatitis B core antibody
             (HBcAb) or hepatitis C serology.

          -  Hemoglobin &lt; 8.0 g/dL.

          -  Concentrations of serum IgG and/or IgM below 5.0 and 0.40 mg/mL, respectively.

          -  Absolute neutrophil count (ANC) &lt; 1.5 X 10³/µL.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filip De Keyser, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCL St. Luc Brussel</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Ghent</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gasthuisberg Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.uzgent.be</url>
    <description>Website University Hospital Ghent</description>
  </link>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2006</study_first_submitted>
  <study_first_submitted_qc>September 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2006</study_first_posted>
  <last_update_submitted>December 4, 2014</last_update_submitted>
  <last_update_submitted_qc>December 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

